Walleye Capital
CNTX icon

Walleye Capital’s Context Therapeutics CNTX Stock Holding History

Walleye Capital’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-132,786
Closed -$195K – 4476
2025
Q4 		$195K Hold
132,786
– – ﹤0.01% 3553
2025
Q3 		$129K Hold
132,786
– – ﹤0.01% 3581
2025
Q2 		$87K Sell
132,786
-36,174
-21% -$26K ﹤0.01% 3839
2025
Q1 		$103K Buy
168,960
+2,654
+2% +$2.31K ﹤0.01% 3608
2024
Q4 		$175K Buy
166,306
+56,651
+52% +$98K ﹤0.01% 3850
2024
Q3 		$215K Buy
109,655
+1,279
+1% +$2.84K ﹤0.01% 3957
2024
Q2 		$217K Buy
+108,376
New +$187K ﹤0.01% 4241

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Walleye Capital's CNTX Position: Q1 2026 in Review

Walleye Capital sold out of Context Therapeutics (CNTX) in Q1 2026, closing a stake of 132,786 shares — an estimated $195K sold.

Walleye Capital first reported a position in CNTX in Q2 2024 and held it in 7 quarters. The position peaked at $217K in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Walleye Capital reported no remaining Context Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 132,786 Context Therapeutics shares in Q1 2026, an estimated $195K.
  • Walleye Capital first reported a position in Context Therapeutics in Q2 2024 and held it in 7 quarters.
  • Walleye Capital's Context Therapeutics position peaked at $217K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.